Apollomics (NASDAQ:APLM) CEO Buys $4,000,005.00 in Stock

Apollomics Inc. (NASDAQ:APLM) CEO Hung-Wen Chen purchased 266,667 shares of Apollomics stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. Following the completion of the transaction, the chief executive officer directly owned 1,029,695 shares of the company’s stock, valued at approximately $15,445,425. The trade was a 34.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Hung-Wen Chen also recently made the following trade(s):

• On Friday, August 14th, Hung-Wen Chen purchased 270,000 shares of Apollomics stock. The stock was bought at an average price of $13.15 per share, with a total value of $3,550,500.00.

Apollomics Stock Down 0.2%

Shares of NASDAQ:APLM traded down $0.04 during trading on Monday, hitting $23.36. 35,072 shares of the company were exchanged, compared to its average volume of 30,338. Apollomics Inc. has a fifty-two week low of $3.66 and a fifty-two week high of $42.12. The firm has a fifty day moving average price of $18.24 and a two-hundred day moving average price of $17.30.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new stake in Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Apollomics presently has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.